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The anthracycline antibiotics are a significant group of drugs for treatment of various types of 
cancer. Difficulties related to their usage are cardiotoxicity and multiple drug resistance. 
Many factors are involved in the development of resistance; one of them is inactivation of 
anthracyclines by the activity of enzymes, human reductases, which are involved in 
biotransformation of anthracyclines by reducing their carbonyl group. Daunorubicin was 
selected from the group of anthracycline antibiotics, in which the potential involvement of 
selected carbonyl reducing enzymes in its metabolism (AKR1A1, AKR1B1, AKR1B10, 
AKR1C1, AKR1C2, AKR1C3, AKR1C4, CBR1 and CBR3) was subject of verification. The 
specific activity of selected reductases was determined by UHPLC analysis of the major 
metabolite, daunorubicinol. The most active reductases were AKR1B10, AKR1C3, AKR1A1 
and CBR1. 
There is a great potential use of cyclin-dependent kinase inhibitors (CDKi) in cancer therapy. 
Expected effect is primarily influencing of cell cycle and blocking of some transporters that 
eliminate anthracyclines from cells. It is expected, that cyclin-dependent kinase inhibitors 
could potentially reduce the activity of carbonyl reducing enzymes. This would cause 
prolongation of their activity in cells as well as increasing efficiency of cytostatics. In my 
research I focused on influence of CDKi on activity of two selected human reductases from 
AKR superfamily (AKR1A1, AKR1B10). Inhibitory effect was determined for following 
CDKi: AT-7519, AZD5438, dinaciclib, flavopiridol, LEE-011, palbociclib, purvalanol A, 
R547 and SNS-032. Whereas the inhibitory effect of tested CDKi on AKR1A1 was 
negligible, AKR1B10 is a suitable target for CDKi, where the greatest inhibitory potential 
was detected mainly in AZD5438 and dinaciclib. 
